Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
Corteria Pharmaceuticals has raised $69.5M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Corteria Pharmaceuticals's investors include OrbiMed, Omnes Capital, Kurma Partners, Jeito Capital, V-Bio Ventures.
Corteria Pharmaceuticals is headquartered in Paris, France.
Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations.
Corteria Pharmaceuticals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Corteria Pharmaceuticals — Funding & Investors." VCBacked, September 7, 2023, https://www.vcbacked.co/company/corteria-pharmaceuticals. Accessed August 1, 2026.
VCBacked. (2023). Corteria Pharmaceuticals — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/corteria-pharmaceuticals
{{cite web |title=Corteria Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/corteria-pharmaceuticals |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated